Liquid chromatography detection method for oseltamivir related substances and application of liquid chromatography detection method
Through high-performance liquid chromatography detection method, the impurities in oseltamivir phosphate granules were separated by gradient elution technology, which solved the problem of separation of multiple impurities in the prior art, and improved the accuracy and safety of drug quality control. .
Patent Information
- Application Number
- CN202411230450.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art cannot effectively separate a variety of impurities in oseltamivir phosphate granules, especially the peak of the sodium peak of the auxiliary material saccharin and the peak of the impurity A, and the elution capacity of impurity VII is insufficient, which affects the quality control of the drug.
Using high-performance liquid chromatography detection method, potassium dihydrogen phosphate solution, methanol and acetonitrile as mobile phases, impurity A and impurity VII were separated by gradient elution technology, which improved the separation of sodium saccharin and impurity A and enhanced impurity VII's elution capacity.
It realizes effective separation of various impurities in oseltamivir phosphate granules, improves the resolution and elution ability, simplifies the analysis process, and ensures the stability and safety of drug quality.
Smart Images

Figure BDA0005025958780000011 
Figure BDA0005025958780000032 
Figure BDA0005025958780000042
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug analysis, and in particular to a liquid chromatography detection method for oseltamivir-related substances and an application thereof. Background Art
[0002] Oseltamivir phosphate is a drug for the treatment and prevention of influenza A and B virus infections in adults and children (specific ages vary by country, including newborns in some cases). It is an oral neuraminidase inhibitor drug, and its metabolite (oseltamivir carboxylate) is a potent and selective influenza virus neuraminidase inhibitor (NI), thereby inhibiting the separation of mature influenza viruses from infected cells, reducing the release of virus particles from infected cells and the further spread of infectious viruses in the human body, thereby playing a role in treating influenza. Oseltamivir phosphate has a therapeutic and preventive effect on influenza caused by subtypes of influenza viruses such as H1N1 and H7N9, and is recommended by my country as the first choice for the treatment of influenza. It is currently available in the United States, Japan, Europe, China and other countries and regions, and the main dosage forms on the market are capsules, dry suspensions and syrups.
[0003] The chemical name of oseltamivir phosphate is (3R, 4R, 5S)-4-acetylamino-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester phosphate. Its structural formula is as follows:
[0004]
[0005] At present, the pharmacopoeias of various countries mainly include oseltamivir phosphate raw materials, oseltamivir phosphate capsules, etc., and none of them include the quality standards for oseltamivir phosphate granules. The same type of oseltamivir phosphate capsules has been launched in the domestic market, and the quality standard is the import registration standard for oseltamivir phosphate capsules, with the standard number JX20140010; ChP2020 and USP43 both include the quality standard for oseltamivir phosphate capsules; the relevant substance detection methods of various pharmacopoeias and the import registration standard for oseltamivir phosphate capsules are all isocratic elution, and the mobile phase composition is basically the same, with only slight differences in the proportion and pH value of the mobile phase. The impurities detected are mainly some process impurities of the oseltamivir phosphate raw materials: Impurity I Impurity II Impurity III However, the raw materials of oseltamivir phosphate granules also contain other process impurities such as impurity IV and possible degradation impurities such as impurity A and impurity V The raw materials of oseltamivir phosphate granules react with the residual reducing sugar in the auxiliary material erythritol to produce impurity VI In addition, the excipients of oseltamivir phosphate granules (trade name: Tamiflu) contain saccharin sodium and acesulfame potassium. Under the chromatographic conditions of the above-mentioned ChP2020 and capsule import registration standards, the retention time of the chromatographic peak of saccharin sodium is close to that of impurity A, which may interfere with the detection of impurities. Under the chromatographic conditions of ChP2020, the elution ability of impurity VII is weak and the retention time is long; under the chromatographic conditions of the capsule import registration standard, the potential degradation impurity V will interfere with the detection of impurity A. That is, the existing technology cannot meet the detection requirements of related substances of oseltamivir phosphate granules, and cannot achieve effective simultaneous separation of multiple impurities. Summary of the invention
[0006] The present invention aims to solve at least one of the above-mentioned technical problems existing in the prior art. To this end, the object of the present invention is to provide a liquid chromatography detection method for oseltamivir-related substances and its application. The method can simply and effectively separate process impurities of oseltamivir phosphate granules raw materials, such as impurity A or impurity VII, wherein when separating impurity A, the peak of saccharin sodium, an auxiliary material of oseltamivir phosphate granules, and the peak of impurity A can be effectively separated.
[0007] In order to achieve the above object, the technical solution adopted by the present invention is:
[0008] The first aspect of the present invention provides a liquid chromatography detection method for oseltamivir-related substances, comprising the following steps:
[0009] High performance liquid chromatography was used to detect oseltamivir-related substances;
[0010] The conditions of the high performance liquid chromatography are: using potassium dihydrogen phosphate solution, methanol and acetonitrile as mobile phases;
[0011] The elution method is: using gradient elution to make the mobile phase pass through the chromatographic column, and then performing ultraviolet detection; from 0 min to at least 50 min, the volume content of the mobile phase A in the mobile phase is 5% to 90%, and the volume content of the mobile phase B in the mobile phase is 10% to 95%;
[0012] The test solution is subjected to high performance liquid chromatography to simultaneously detect oseltamivir-related substances; the oseltamivir-related substances are impurities generated during the production process of oseltamivir.
[0013] In some embodiments of the present invention, the oseltamivir-related substance comprises:
[0014] In some embodiments of the present invention, the oseltamivir-related substance includes and at least one of the following:
[0015] In some embodiments of the present invention, potassium dihydrogen phosphate solution: methanol: acetonitrile = 880-710: 50-210: 60-100 (v:v:v) is used as mobile phase A, and potassium dihydrogen phosphate solution: methanol: acetonitrile = 530-600: 200-380: 250-100 (v:v:v) is used as mobile phase B; wherein the concentrations of the potassium dihydrogen phosphate solutions in mobile phase A and mobile phase B are each independently 0.01 mol / L to 0.10 mol / L.
[0016] In some embodiments of the present invention, potassium dihydrogen phosphate solution: methanol: acetonitrile = 850-710: 70-210: 80 (v:v:v) is used as mobile phase A, and potassium dihydrogen phosphate solution: methanol: acetonitrile = 560-600: 220-380: 220-100 (v:v:v) is used as mobile phase B; wherein the concentrations of the potassium dihydrogen phosphate solutions in mobile phase A and mobile phase B are each independently 0.02 mol / L to 0.07 mol / L.
[0017] In some embodiments of the present invention, potassium dihydrogen phosphate solution: methanol: acetonitrile = 850-780: 70-180: 80 (v:v:v) is used as mobile phase A, and potassium dihydrogen phosphate solution: methanol: acetonitrile = 560-580: 220-330: 220-100 (v:v:v) is used as mobile phase B; wherein the concentrations of the potassium dihydrogen phosphate solutions in mobile phase A and mobile phase B are each independently 0.03 mol / L to 0.07 mol / L.
[0018] In some embodiments of the present invention, the pH of the mobile phase A is 5.0-7.0, such as 5.5-6.5, 5.8-6.2, 6.0±0.2, etc. The mobile phase A uses an alkaline reagent to adjust the pH, and the alkaline reagent includes 0.5-1.5 mol / L potassium hydroxide solution.
[0019] In some embodiments of the present invention, the pH of the mobile phase B is 5.0-7.0, such as 5.5-6.5, 5.8-6.2, 6.0±0.2, etc. The mobile phase B uses an alkaline reagent to adjust the pH, and the alkaline reagent includes 0.5-1.5 mol / L potassium hydroxide solution.
[0020] In some embodiments of the present invention, the gradient elution method specifically includes:
[0021] S1: the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 70% to 90% (e.g., 75%, 85%, 90%), and the volume content of the mobile phase B in the mobile phase is 10% to 30%; the elution time is 3 to 7 minutes (e.g., 5 minutes);
[0022] S2: Switch the mobile phase, the volume content of the mobile phase A in the mobile phase is reduced from 70% to 90% (such as 75%, 85%, 90%) to 1% to 10% (such as 5%), and the volume content of the mobile phase B in the mobile phase is increased from 10% to 30% (such as 25%) to 90% to 99% (such as 75%, 90%, 95%); the elution time is 24 to 36 minutes (such as 25 to 35 minutes, 30 minutes);
[0023] S3: Switch the mobile phase, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 1% to 10% (e.g., 5%), and the volume content of the mobile phase B in the mobile phase is 90% to 99% (e.g., 75%, 90%, 95%); the elution time is 10 to 20 min (e.g., 15 min);
[0024] S4: switching the mobile phase, the volume content of the mobile phase A in the mobile phase increases from 1% to 10% (e.g., 5%) to 70% to 90% (e.g., 75%), and the volume content of the mobile phase B in the mobile phase decreases from 90% to 99% (e.g., 75%, 90%, 95%) to 10% to 30%; the elution time is 0.01 to 1.5 min (e.g., 1.0 min);
[0025] S5: Switch the mobile phase, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 70% to 90% (e.g., 75%), and the volume content of the mobile phase B in the mobile phase is 10% to 30% (e.g., 25%); the elution time is 9 to 10 min (e.g., 9.99 min).
[0026] In some embodiments of the present invention, the gradient elution method specifically includes:
[0027] S2 includes: S2-1: switching the mobile phase, the volume content of the mobile phase A in the mobile phase decreases from 70% to 80% to 20% to 30%, and the volume content of the mobile phase B in the mobile phase increases from 20% to 30% to 70% to 80%; the elution time is 12 to 18 minutes (such as 15 minutes); S2-2: switching the mobile phase, the volume content of the mobile phase A in the mobile phase decreases from 20% to 30% to 1% to 10%, and the volume content of the mobile phase B in the mobile phase increases from 70% to 80% to 90% to 99%; the elution time is 12 to 18 minutes (such as 15 minutes).
[0028] In some embodiments of the present invention, the gradient elution method specifically includes:
[0029] At 0 to 5 minutes, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 70% to 80%, and the volume content of the mobile phase B in the mobile phase is 20% to 30%;
[0030] In 5 to 20 minutes, the volume content of the mobile phase A in the mobile phase decreases from 70% to 80% to 20% to 30%, and the volume content of the mobile phase B in the mobile phase increases from 20% to 30% to 70% to 80%;
[0031] At 20 to 35 minutes, the volume content of the mobile phase A in the mobile phase decreases from 20% to 30% to 1% to 10%, and the volume content of the mobile phase B in the mobile phase increases from 70% to 80% to 90% to 99%;
[0032] At 35 to 50 minutes, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 1% to 10%, and the volume content of the mobile phase B in the mobile phase is 90% to 99%;
[0033] At 50-51 minutes, the volume content of the mobile phase A in the mobile phase increases from 1%-10% to 70%-80%, and the volume content of the mobile phase B in the mobile phase decreases from 90%-99% to 20%-30%;
[0034] At 51 to 60 minutes, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 70% to 80%, and the volume content of the mobile phase B in the mobile phase is 20% to 30%.
[0035] In some embodiments of the present invention, the gradient elution method specifically includes:
[0036] At 0 to 5 minutes, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 72% to 78%, and the volume content of the mobile phase B in the mobile phase is 22% to 28%;
[0037] In 5 to 20 minutes, the volume content of the mobile phase A in the mobile phase decreases from 72% to 78% to 22% to 28%, and the volume content of the mobile phase B in the mobile phase increases from 22% to 28% to 72% to 78%;
[0038] At 20 to 35 minutes, the volume content of the mobile phase A in the mobile phase decreases from 22% to 28% to 3% to 7%, and the volume content of the mobile phase B in the mobile phase increases from 72% to 78% to 93% to 97%;
[0039] At 35 to 50 minutes, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 3% to 7%, and the volume content of the mobile phase B in the mobile phase is 93% to 97%;
[0040] At 50-51 minutes, the volume content of the mobile phase A in the mobile phase increases from 3%-7% to 72%-78%, and the volume content of the mobile phase B in the mobile phase decreases from 93%-97% to 22%-28%;
[0041] At 51 to 60 minutes, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 72% to 78%, and the volume content of the mobile phase B in the mobile phase is 22% to 28%.
[0042] In some embodiments of the present invention, the gradient elution method specifically includes:
[0043] In the period from 0 to 5 minutes, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 75%, and the volume content of the mobile phase B in the mobile phase is 25%;
[0044] In 5 to 20 minutes, the volume content of the mobile phase A in the mobile phase decreases from 75% to 25%, and the volume content of the mobile phase B in the mobile phase increases from 25% to 75%;
[0045] In the range of 20 to 35 minutes, the volume content of the mobile phase A in the mobile phase decreases from 25% to 5%, and the volume content of the mobile phase B in the mobile phase increases from 75% to 95%;
[0046] At 35 to 50 minutes, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 3% to 7%, and the volume content of the mobile phase B in the mobile phase is 95%;
[0047] At 50-51 minutes, the volume content of the mobile phase A in the mobile phase increases from 5% to 75%, and the volume content of the mobile phase B in the mobile phase decreases from 95% to 25%;
[0048] At 51 to 60 minutes, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 75%, and the volume content of the mobile phase B in the mobile phase is 25%.
[0049] In some embodiments of the present invention, the chromatographic column is a chromatographic column using octylsilane bonded silica gel as a filler.
[0050] In some embodiments of the present invention, in the mobile phase, (i) the particle size of the chromatographic column is 3.0-5.0 μm and the size is 4.6×250 mm; and / or, (ii) the chromatographic column model is ACE EXCELC8, Agilent ZorbaxEclipse Plus C8, Shim-pack XR-C8, YMC-Triart C8 or Welch XtimateC8.
[0051] In some embodiments of the present invention, the detection wavelength in the HPLC detection process is 200 nm to 220 nm, such as 205 nm to 215 nm, 205 nm to 209 nm, or 207 nm.
[0052] In some embodiments of the present invention, the mobile phase flow rate during the HPLC detection process is 0.5-2 mL / min, such as 0.8-1.7 mL / min, 1.0-1.3 mL / min, 1.2 mL / min.
[0053] In some embodiments of the present invention, the column temperature of the chromatographic column is 45-55°C, such as 48-52°C, 50°C.
[0054] In some embodiments of the present invention, the injection volume in the HPLC detection process is 15-35 μL, such as 20-30 μL, 25 μL.
[0055] In some embodiments of the present invention, the liquid chromatography detection method of oseltamivir-related substances comprises the following steps:
[0056] (1): Preparation of system suitability solution: Take appropriate amounts of impurity I to impurity VII reference substances, impurity A reference substance and oseltamivir phosphate reference substance, add solvent to dissolve and quantitatively dilute to form a system suitability solution;
[0057] (2): Preparation of test solution: Take an appropriate amount of oseltamivir phosphate granules, dissolve and dilute with a solvent to prepare a test solution;
[0058] (3): Preparation of blank excipient solution: Take an appropriate amount of blank excipient of oseltamivir phosphate granules, dissolve and dilute with a solvent to prepare a blank excipient solution;
[0059] (4) Chromatographic test: Take appropriate amounts of system suitability solution, test sample solution and blank excipient solution, inject them into liquid chromatograph and record the chromatogram.
[0060] In some embodiments of the present invention, the liquid chromatography detection method of oseltamivir-related substances comprises the following steps:
[0061] (1): Preparation of system suitability solution: Take appropriate amounts of impurity I to impurity VII reference substances, impurity A reference substance and oseltamivir phosphate reference substance, dissolve them in solvent and quantitatively dilute them into a mixed solution containing approximately 2.2 μg of impurity I, 2.2 μg of impurity III, 1.5 μg of impurity II, impurity IV to impurity VII, and impurity A, and 1 mg of oseltamivir phosphate per 1 mL;
[0062] (2): Preparation of the test solution: Take an appropriate amount of oseltamivir phosphate granules (equivalent to 50 mg of oseltamivir; weigh the sample according to the weight per milligram), place it in a 50 mL volumetric flask, add an appropriate amount of solvent, ultrasonically shake for 15 minutes to dissolve the oseltamivir phosphate, cool, dilute to the scale with solvent, shake well, filter, and take the filtrate as the test solution;
[0063] (3): Preparation of blank excipient solution: Accurately weigh about 1.24 g of blank excipient of oseltamivir phosphate granules, place in a 50 mL volumetric flask, add an appropriate amount of solvent, ultrasonically shake for 15 minutes to dissolve oseltamivir phosphate, cool, dilute to scale with solvent, shake well, filter, and take the filtrate as the blank excipient solution;
[0064] (4) Chromatographic test: Take appropriate amounts of system suitability solution, test sample solution and blank excipient solution, inject them into liquid chromatograph and record the chromatogram.
[0065] The second aspect of the present invention provides a method for preparing oseltamivir, comprising using the liquid chromatography detection method for oseltamivir-related substances for detection.
[0066] The beneficial effects of the present invention are:
[0067] 1. The method of the present invention not only effectively separates the saccharin sodium peak and the impurity A peak of the oseltamivir phosphate granules excipient, but also enhances the elution ability of the impurity VII. The mobile phase reagent and chromatographic column in the method are extremely common, highly applicable, highly sensitive, and short in analysis time, which can better safeguard the control of related substances in the entire life cycle of the oseltamivir phosphate granules.
[0068] 2. The advantageous technical solution of the present invention can simultaneously separate impurities I to VII, impurity A with good separation, and the main degradation impurities under various strong degradation and stability conditions, and realizes the effective separation of the auxiliary material saccharin sodium peak and the impurity A peak in the oseltamivir phosphate granules, while enhancing the elution ability of impurity VII, shortening the injection time, and also improving the separation degree of potential degradation impurity V and impurity A.
[0069] 3. The detection method used in the present invention has strong separation ability, simple operation process, strong specificity, and the auxiliary material peak does not interfere with the detection. It is more convenient to operate and can more effectively achieve quality control of the product production process, improve the quality of the final product, and ensure the safety and effectiveness of clinical drug use.
[0070] 4. The detection method of the present invention has high sensitivity, high accuracy, good repeatability and a short detection time period, providing a simpler, more stable and reliable analysis and detection method for product development and production processes. BRIEF DESCRIPTION OF THE DRAWINGS
[0071] Figure 1 This is a chromatogram of the mixed solution under test condition 1 of Example 1 of the present invention.
[0072] Figure 2 This is a chromatogram of the mixed solution under test condition 2 of Example 1 of the present invention.
[0073] Figure 3 This is a chromatogram of the mixed solution under test condition 3 of Example 1 of the present invention.
[0074] Figure 4 This is the chromatogram of the sensitivity solution under test condition 4 of Example 1 of the present invention.
[0075] Figure 5 In the chromatogram of the test sample solution under test condition 4 of Example 1 of the present invention, impurity IV peaks at the gradient change.
[0076] Figure 6 This is the solution chromatogram of system suitability under test condition 5 of Example 1 of the present invention.
[0077] Figure 7 This is the solution chromatogram of the system suitability of Example 2 of the present invention.
[0078] Figure 8 It is the chromatogram of blank auxiliary material solution of Example 2 of the present invention.
[0079] Fig. 9 This is the sensitivity solution chromatogram of Example 2 of the present invention.
[0080] Fig.10 This is a linear trend diagram of the related substance inspection in Example 6 of the present invention.
[0081] Fig.11 This is a chromatogram of the mixed solution of Comparative Example 1 of the present invention. DETAILED DESCRIPTION
[0082] The present invention is further described in detail below by specific examples. Unless otherwise specified, the raw materials, reagents or devices used in the examples and comparative examples can be obtained from conventional commercial sources or can be obtained by prior art methods. Unless otherwise specified, the experiments or test methods are conventional methods in the art.
[0083] Instruments and reagents
[0084] Instrument: Agilent 1260II high performance liquid chromatograph / Thermo Ultimate 3000 high performance liquid chromatograph, UV detector.
[0085] Reagents: Potassium dihydrogen phosphate, potassium hydroxide, and phosphoric acid were all analytical grade, and methanol and acetonitrile were chromatographic grade. Oseltamivir phosphate reference substances were independently calibrated using oseltamivir phosphate raw materials, and impurity reference substances were purchased externally.
[0086] Oseltamivir phosphate granules (trade name: Tamiflu)
[0087] Solvent: 0.003 mol / L phosphoric acid solution-methanol-acetonitrile (780:140:80)
[0088] Preparation of system suitability solution: Take appropriate amounts of impurity I to impurity VII reference substances, impurity A reference substance and oseltamivir phosphate reference substance, dissolve in solvent and quantitatively dilute to a mixed solution containing approximately 2.2 μg of impurity I, 2.2 μg of impurity III, 1.5 μg of impurity II, impurity IV to impurity VII, and impurity A per mL, and 1 mg of oseltamivir phosphate;
[0089] Preparation of the test solution: Take the oseltamivir phosphate granules, accurately weigh an appropriate amount (equivalent to 50 mg of oseltamivir; according to the measured weight per milligram, it is used for sample conversion), put it in a 50mL volumetric flask, add an appropriate amount of solvent, ultrasonically shake for 15 minutes to dissolve the oseltamivir phosphate, cool, dilute to the scale with solvent, shake well, filter, and take the filtrate as the test solution;
[0090] Preparation of blank excipient solution: accurately weigh about 1.24 g of blank excipient of oseltamivir phosphate granules, place in a 50 mL volumetric flask, add an appropriate amount of solvent, ultrasonically shake for 15 minutes to dissolve it, cool, dilute to the scale with solvent, shake well, filter, and take the filtrate as the blank excipient solution;
[0091] Preparation of sensitivity solution: Accurately measure 5 mL of oseltamivir phosphate reference solution, place it in a 20 mL volumetric flask, dilute to the scale with diluent, shake well, and obtain.
[0092] Preparation of mixed solution: Take appropriate amounts of impurity I to impurity VII reference substances, impurity A reference substance, oseltamivir phosphate reference substance and excipient saccharin sodium, dissolve in solvent and quantitatively dilute to a mixed solution containing approximately 2.2 μg of impurity I, 2.2 μg of impurity III, 1.5 μg of impurities IV to impurity VII and impurity A, 25 μg of excipient saccharin sodium and 1 mg of oseltamivir per 1 mL.
[0093] Preparation of mixed impurity stock solution for spiked use: Weigh approximately 11 mg of impurity I reference substance, approximately 7.5 mg of impurity II, approximately 17.5 mg of impurity III, approximately 7.5 mg of impurity IV, approximately 7.5 mg of impurity A, approximately 7.5 mg of impurity V, approximately 8 mg of impurity VI, and approximately 10 mg of impurity VII, accurately weigh, place in the same 100 mL volumetric flask, add appropriate amount of diluent to dissolve and dilute to the scale, shake well, and use as the mixed impurity stock solution.
[0094] Preparation of the test sample spiked solution: Take 10 g of oseltamivir phosphate granules, grind and mix evenly, take about 1.27 g (equivalent to 50 mg of oseltamivir phosphate), accurately weigh, place in a 50 mL volumetric flask, add an appropriate amount of diluent, sonicate for 15 min, accurately add 1.0 mL of mixed impurity stock solution for spiked, dilute to the scale with diluent, shake well, filter, and take the filtrate to obtain.
[0095] Example 1
[0096] This example screens the chromatographic conditions in the high performance liquid chromatography detection method for oseltamivir-related substances, and the specific process is as follows:
[0097] Take the solution under the instrument and reagent item for detection and analysis. Liquid chromatography conditions: octylsilane bonded silica gel as a filler column (ACE EXCELC8 4.6×250mm, 5μm or a column with equivalent performance.), mobile phase, gradient elution program table injection volume see Table 1, UV detection wavelength 207nm, flow rate 1.2mL / min, column temperature 50℃, record chromatogram.
[0098] Table 1
[0099]
[0100]
[0101] Test results:
[0102] Test condition 1: In the chromatogram of the mixed solution, the separation of the excipient saccharin sodium, impurity A, impurity V (impurity 14) and impurity III all met the requirements, and the chromatographic peaks of impurity II and impurity I overlapped, as shown in Figure 1. Figure 1 Marked in red.
[0103] Test condition 2: The separation of excipient saccharin sodium, impurity A, impurity V (impurity 14) and impurity III in the chromatogram of the mixed solution meets the requirements, and the separation of impurity II and impurity I is 1.2. Figure 2 .
[0104] Test condition 3: The separation degree of each impurity in the chromatogram of the mixed solution meets the requirements, see Figure 3 However, the sensitivity of impurity detection in the test solution becomes smaller. Therefore, the injection volume is adjusted, and the sensitivity solution is taken and tested according to test condition 4.
[0105] Test condition 4: In the sensitivity solution chromatography, the sensitivity solution signal-to-noise ratio is greater than 10. Figure 4 In the subsequent quality research process, it was found that when the sample was tested according to test condition 4, factors such as mobile phase preparation, detection instrument, and chromatographic column changes would cause a slight change in the retention time of impurity IV, which could cause it to elute at the gradient elution change point, but impurity IV could still be well separated (see Figure 5 Marked in red), so the gradient elution table needs to be adjusted.
[0106] Test condition 5: System suitability solution chromatogram The excipients do not interfere with the detection of known impurities, and the separation of each impurity meets the requirements, see Figure 6 .
[0107] In summary, from the screening results of the chromatographic conditions in Table 1, it can be seen that test conditions 1 to 5 can effectively separate and determine impurity VII and impurity A, among which the separation degree of the oseltamivir phosphate peak and the adjacent impurity preparation and the separation degree between impurities in the chromatographic condition of test condition 5 meet the requirements, and the excipient peak does not interfere with the detection of related substances. Test condition 5 was used as the optimal chromatographic condition for methodological verification.
[0108] Example 2
[0109] This example conducts a specificity test on the HPLC detection method of oseltamivir related substances, and the specific process is as follows:
[0110] Oseltamivir phosphate reference substance and each impurity reference substance were taken and measured according to the optimal determination method screened in Example 1 above. The system suitability test results are shown in Tables 2 and Figure 7 In the system suitability chromatogram, impurity A, impurity V, impurity III, impurity II, impurity I, oseltamivir, impurity VI, impurity IV and impurity VII appeared in sequence, and the separation between each chromatographic peak was greater than 1.5, with good separation. Take 25 μL of blank excipient solution, inject it into the liquid chromatograph, record the chromatogram, and refer to the results. Figure 8 The blank auxiliary material peak and the blank solvent peak both appeared before 3.2 minutes, and there was no interference with the detection of impurities of related substances. Take 25μL of the sensitivity solution, inject it into the liquid chromatograph, and record the chromatogram. The results are shown in Fig. 9The signal-to-noise ratio of the main component peak of the sensitivity solution is 57.7, which is greater than 10. The method has good specificity.
[0111] Table 2
[0112]
[0113] Example 3
[0114] This example conducts an accuracy test on the HPLC detection method of oseltamivir related substances, and the specific process is as follows:
[0115] The accuracy of the method was achieved by examining the accuracy solution of different amounts of impurity reference substance stock solution added to the blank excipient. The concentrations of each impurity examined included 50% of the limit concentration, the limit concentration, and 150% of the limit concentration. Three copies were prepared in parallel for each concentration, and the mean recovery rate and relative standard deviation met the requirements. The method has good accuracy, and the results are shown in Table 3.
[0116] Table 3
[0117]
[0118]
[0119] Example 4
[0120] This example conducts a precision test on the HPLC detection method of oseltamivir related substances, and the specific process is as follows:
[0121] The precision test was conducted by repeatability and intermediate precision. Repeatability was tested by preparing 6 samples of 100% spiked test solution in parallel, and the recovery and relative standard deviation were calculated by the main component external standard method and impurity external standard method with correction factors. The difference between the results of the two methods was calculated. Intermediate precision was verified by repeatability by different personnel, dates, and instruments; and the relative standard deviation was calculated for the 12 results. The results are shown in Tables 4, 5, and 6.
[0122] The difference in the content of each known impurity of this product calculated by the impurity external standard method and the main component external standard method with correction factor is less than 0.04%, and the difference in total impurities is 0.08%, that is, there is no significant difference in the related substances of this product calculated by the impurity external standard method and the main component external standard method with correction factor. This method has good precision.
[0123] Table 4
[0124]
[0125] Table 5
[0126]
[0127] Table 6
[0128]
[0129] Example 5
[0130] This example conducts a detection limit and quantitation limit test on the HPLC detection method of oseltamivir related substances. The specific process is as follows:
[0131] Take appropriate amount of oseltamivir phosphate and each impurity reference substance, dissolve with solvent and gradually dilute, shake well, accurately measure 25 μL and inject into liquid chromatograph until the signal-to-noise ratio of each component peak is 10 and 3, which is the quantitative limit and detection limit of the corresponding component, and the quantitative limit solution is injected six times continuously, and the relative standard deviation of the peak area is not more than 10.0%. The results are shown in Table 7.
[0132] Table 7
[0133]
[0134]
[0135] Example 6
[0136] This example conducts a linearity test on the HPLC detection method of oseltamivir related substances, and the specific process is as follows:
[0137] The linearity of the method was achieved by examining the linearity of at least six solutions of different concentrations, including the quantitative limit. The measured peak area was plotted against the concentration, and the regression equation, correlation coefficient and intercept were calculated using the least squares method. The method had good linearity, as shown in Table 8. Fig.10 .
[0138] Table 8
[0139]
[0140] Example 7
[0141] This example conducts a durability test on the HPLC detection method of oseltamivir related substances, and the specific process is as follows:
[0142] The durability of the method was investigated by changing the chromatographic column batch, column temperature, detection wavelength, and flow rate. Compared with the standard conditions, the system suitability test met the standard requirements under each variable chromatographic parameter, and the number of impurities in the chromatogram of the test solution was consistent (content greater than 0.05%), the impurity content was 0.05% to 0.5%, and the RSD value was less than 10.0%; the impurity content was 0.5% to 2%, and the RSD value was less than 5.0%. It met the acceptance criteria, indicating that the method has good durability by fine-tuning the detection wavelength, flow rate, column temperature, and using different chromatographic column batches in the chromatographic parameters. The results are shown in Tables 9 and 10.
[0143] Table 9
[0144]
[0145] Table 10
[0146]
[0147] Comparative Example 1
[0148] This comparative example uses a high performance liquid chromatography method to detect oseltamivir-related substances, and the specific process is as follows:
[0149] This test example was carried out with reference to Example 1, but the chromatographic conditions were as shown in Table 11.
[0150] Table 11
[0151]
[0152] Using the chromatographic conditions of Comparative Example 1, each positioning solution was sampled. The retention time of the chromatographic peaks of saccharin sodium and acesulfame potassium in the chromatogram was close to the retention time of impurity A, which may interfere with impurity detection; and the elution ability of impurity VII was weak and the retention time was long. The results are shown in Tables 12 and Fig.11 .
[0153] Table 12
[0154]
[0155]
[0156] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A liquid chromatography detection method for oseltamivir related substances, characterized in that: The following steps are involved: High performance liquid chromatography was used to detect oseltamivir-related substances; The conditions of the high performance liquid chromatography are: potassium dihydrogen phosphate solution, methanol and acetonitrile are used as mobile phase A and mobile phase B respectively; The elution method is: using gradient elution to make the mobile phase pass through the chromatographic column, and then performing ultraviolet detection; from 0 min to at least 50 min, the volume content of the mobile phase A in the mobile phase is 5% to 90%, and the volume content of the mobile phase B in the mobile phase is 10% to 95%; The test solution is subjected to high performance liquid chromatography to simultaneously detect oseltamivir-related substances; the oseltamivir-related substances are impurities generated during the production process of oseltamivir.
2. The liquid chromatography detection method for oseltamivir related substances according to claim 1, characterized in that: The oseltamivir-related substances include:
3. The liquid chromatography detection method for oseltamivir related substances according to claim 1, characterized in that: The oseltamivir-related substances include and / or and at least one of the following:
4. The liquid chromatography detection method for oseltamivir related substances according to claim 1, characterized in that: The mobile phase A is potassium dihydrogen phosphate solution: methanol: acetonitrile = 880-710: 50-210: 60-100 (v:v:v), and the mobile phase B is potassium dihydrogen phosphate solution: methanol: acetonitrile = 530-600: 200-380: 250-100 (v:v:v); wherein the concentrations of the potassium dihydrogen phosphate solutions in the mobile phase A and the mobile phase B are each independently 0.01 mol / L to 0.10 mol / L.
5. The liquid chromatography detection method for oseltamivir related substances according to claim 1, characterized in that: The gradient elution method specifically includes: S1: the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 70% to 90%, and the volume content of the mobile phase B in the mobile phase is 10% to 30%; the elution time is 3 to 7 minutes; S2: Switch the mobile phase, the volume content of the mobile phase A in the mobile phase decreases from 70% to 90% to 1% to 10%, and the volume content of the mobile phase B in the mobile phase increases from 10% to 30% to 90% to 99%; the elution time is 24 to 36 minutes; S3: Switch the mobile phase, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 1% to 10%, and the volume content of the mobile phase B in the mobile phase is 90% to 99%; the elution time is 10 to 20 min; S4: switching the mobile phase, the volume content of the mobile phase A in the mobile phase increases from 1% to 10% to 70% to 90%, and the volume content of the mobile phase B in the mobile phase decreases from 90% to 99% to 10% to 30%; the elution time is 0.01 to 1.5 min; S5: Switch the mobile phase, the mobile phase A and the mobile phase B are subjected to isocratic elution, the volume content of the mobile phase A in the mobile phase is 70% to 90%, and the volume content of the mobile phase B in the mobile phase is 10% to 30%; the elution time is 9 to 10 minutes.
6. The liquid chromatography detection method for oseltamivir related substances according to claim 5, characterized in that: The gradient elution method specifically includes: S2 includes: S2-1: switching the mobile phase, the volume content of the mobile phase A in the mobile phase decreases from 70% to 80% to 20% to 30%, and the volume content of the mobile phase B in the mobile phase increases from 20% to 30% to 70% to 80%; the elution time is 12 to 18 minutes; S2-2: switching the mobile phase, the volume content of the mobile phase A in the mobile phase decreases from 20% to 30% to 1% to 10%, and the volume content of the mobile phase B in the mobile phase increases from 70% to 80% to 90% to 99%; the elution time is 12 to 18 minutes.
7. The liquid chromatography detection method for oseltamivir related substances according to claim 1, characterized in that: In the mobile phase, (i) the particle size of the chromatographic column is 3.0-5.0 μm and the size is 4.6×250 mm; and / or, (ii) the chromatographic column model is ACE EXCELC8, Agilent Zorbax Eclipse Plus C8, Shim-pack XR-C8, YMC-TriartC8 or Welch XtimateC8.
8. The liquid chromatography detection method for oseltamivir related substances according to claim 1, characterized in that: The conditions of the high performance liquid chromatography at least meet any of the following conditions: (i) the pH of the mobile phase A or the mobile phase B is 5.0 to 7.0; (ii) the detection wavelength in the HPLC detection process is 200 nm to 220 nm; (iii) the mobile phase flow rate during the HPLC detection process is 0.5 to 2 mL / min; (iv) the column temperature of the chromatographic column is 45 to 55° C.; (v) The injection volume during the HPLC detection process is 15 to 35 μL.
9. The liquid chromatography detection method for oseltamivir related substances according to claim 1, characterized in that: The liquid chromatography detection method of oseltamivir related substances comprises the following steps: (1): Preparation of system suitability solution: Take appropriate amounts of impurity I to impurity VII reference substances, impurity A reference substance and oseltamivir phosphate reference substance, add solvent to dissolve and quantitatively dilute to form a system suitability solution; (2): Preparation of test solution: Take an appropriate amount of oseltamivir phosphate granules, dissolve and dilute with a solvent to prepare a test solution; (3): Preparation of blank excipient solution: Take an appropriate amount of blank excipient of oseltamivir phosphate granules, dissolve and dilute with a solvent to prepare a blank excipient solution; (4) Chromatographic test: Take appropriate amounts of system suitability solution, test sample solution and blank excipient solution, inject them into liquid chromatograph and record the chromatogram.
10. A method for preparing oseltamivir, comprising detecting oseltamivir-related substances using the liquid chromatography detection method of any one of claims 1 to 9.
Citation Information
Patent Citations
High performance liquid chromatography method for separating and measuring oseltamivir phosphate and specific impurities of oseltamivir phosphate
CN109580850A
Pharmaceutical composition of oseltamivir phosphate coated particles, as well as application and preparation method
CN112121027A
Oseltamivir phosphate oral composition
CN117298089A
